After Johnson & Johnson's Zytiga put up notable prostate cancer data, Astellas and Pfizer needed a win for their medicine Xtandi. Now they have one.
Teva Pharmaceutical offered Lundbeck CEO Kåre Schultz a pay package worth up to $52 million to join as its leader.
Following a sales fraud investigation that led to major executive changes, Alexion’s new management is rolling out its first corporate revamp.
Seeking to shield itself against a “double jeopardy” of IP challenges, Allergan has transferred key Restasis patents to the Saint Regis Mohawk Tribe.
Bristol-Myers' immunotherapy Opdivo cut the risk of a melanoma recurrence by 35% compared with its sister med Yervoy, a new study found.
Under mounting pressure in diabetes, Eli Lilly has just become the latest drugmaker to undergo a major shakeup.
Vas Narasimhan will take over as CEO of Novartis in February 2018 and will be inheriting several challenges, not the least of which is pricing pressure on both…
Kite investors are set for big gains with Gilead Sciences’ $180-per-share buyout—and founder Arie Belldegrun will reap a $597 million of that payday.
Novartis's groundbreaking CAR-T med won FDA approval Wednesday, but debate over pricing—and the company's responses—are just beginning.
Sanofi’s loss is Almirall’s gain. In its second diabetes exec shift since last May, EVP Peter Guenter jumped to the top job at derm-focused Almirall.